

### NORepinephrine 32 mg/250 mL D5W

#### SUPPLIES

*include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed*

**\*\*\*NS flush syringes are never to be used for reconstitution/diluent for medication.\*\*\***

- Eight (8) NORepinephrine 1 mg/mL injection vials 4 mL
- One (1) dextrose 5% in water (D5W) 250 mL
- Alcohol swabs
- Two (2) 18 gauge needles preferred (20-23 gauge needles acceptable)
- Two (2) 50 mL sterile IV syringes
- Nursing IV admixture label(s) – Lawson # 626

#### STEPS

*explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.)*

1. Wash hands. Prepare/clean the designated mixing area.
2. Flip the cap off of the NORepinephrine 1 mg/mL injection vials, wipe the rubber stoppers with alcohol swab, and wipe the injection port of the D5W bag.
3. Attach 18 gauge needle to syringe. Withdraw 32 mL from D5W bag and discard syringe with needle into a sharp container.
4. Attach 18 gauge needle to another syringe. Withdraw 32 mL of NORepinephrine 1 mg/mL injection.
5. Transfer 32 mL of NORepinephrine 1 mg/mL injection into the D5W bag, and discard syringe with needle into a sharp container.
6. Gently invert bag to mix. Do not shake. Visually inspect solution (e.g. free of inappropriate visible particulates or other foreign matter, discoloration, and defect), and the container integrity is intact. Discard if any defects.
7. Label the NORepinephrine 32 mg/250 mL D5W bag with:
  - a. Drug name, strength, and dose (if not apparent by the container)
  - b. Diluent and volume (if not apparent by the container)
  - c. Hang-by date and time (**Administration must begin within 1 hour from the time of compounding**)
  - d. Initials of person compounding

#### NOTES

*explicitly state (if applicable) any pertinent information*

- Protect final product from light. Cover with light protected plastic bag (e.g. brown plastic bag).

#### References

- NORepinephrine injection [prescribing information]. Morgantown, WV: Mylan Institutional LLC. Revised: 10/2021.  
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d3ea12e0-88cc-49b0-b06e-5199ecd6ca69&type=display>.
- United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF. Rockville, MD: United States Pharmacopeia.  
<https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness>.